Supplementary Figure S1.

Slides:

Advertisements

Similar presentations

(+++) Normal breast ATM (++) IDC ATM Lymph node metastasis negative positive P-value A B X200 C Vector ATM - WT.

Advertisements

(hr) Cleaved Caspase-9 Caspase nM Paclitaxel MCF-7 Figure S1a.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Training Set Clinicopathological parameters of the training set

Progesterone receptor

Neal et al.Supplementary Figure S1

Figure S1. qPCR analysis of the EMT markers ZEB2 and SNAI1 in Syndecan-1 and control siRNA transfected MDA-MB-231 and MCF-7 cells reveals no significant.

A B C MDA-MB-231 OHT: h FOXM1 PLK CDC25b ERα Tubulin

سرطان الثدي Breast Cancer

Nor Supp.Fig. S1 Raja et al. a b c d e f 1 2 Hyp - + Hyp - +

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

A. D. B. C. - ΔNP63α - β-Actin IMEC - SUM MDA-MB IMEC

Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice

Roles of systemic versus tumour SK1 in the regulation of local tumour growth and lung colonization/metastasis.A.Effects of siRNA‐mediated SK1 knockdown.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

to the liver and promote patient-derived xenograft tumour growth

Volume 6, Issue 5, Pages (March 2014)

Triple‐negative breast cancer (TNBC) cells in human express a specific gene signature and their self‐renewal depends on canonical Wnt/β‐catenin signalling.A.Human.

(A-B) Expression of dominant negative p73. (C) Knockdown of p73

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Validation of St6GalNAc2 as a metastasis suppressor gene.

Supplementary Table 1.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Figure S4 control-siRNA Day 0 fes A-siRNA Day 3 fer 1-siRNA

Stable and Potent Selenomab-Drug Conjugates

Supplementary Figure S4

Molecular Therapy - Nucleic Acids

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Volume 18, Issue 12, Pages (March 2017)

Volume 6, Issue 3, Pages (September 2002)

Activity of MAC-321 (i. v. and p. o

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. A,

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

CD151 effects on mammary cell morphology and adhesion.

Specific recognition of HOM-MEL-40/SSX2-derived p pulsed targets by p stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast.

Figure 4. MicroRNA (miR)-195 and miR-497 directly targets CD274

TFAP2A knockdown inhibits tumor growth in vivo.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

coTCRcys-transduced T cells control tumor growth in vivo.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

Matriptase-2 inhibited breast tumor development in vivo.

Depletion of HDAC2 sensitizes cells to epirubicin-induced apoptosis.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.

Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells. Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells.

Activation of Ccl2–Ccr2 pathway is required for mammary carcinogenesis induced by Rb deficiency. Activation of Ccl2–Ccr2 pathway is required for mammary.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

Supplementary Fig. 1.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. A,

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

Fig. 3. PTEN a target of miR-182-5p

TAE-684 effectively inhibits the growth of H3122 in vivo.

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

RRP1B interacts with TRIM28 and HP1α at regions associated with H3K9me3 and decreased gene expression. RRP1B interacts with TRIM28 and HP1α at regions.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

Curative effect of W+T treatment in vivo.

AMG 176 exhibits robust single-agent activity in vivo.

Inhibition of HDACs disrupts DNMT1 association with Hsp90.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Presentation transcript:

Supplementary Figure S1. Campbell et al., MCL-1 in breast cancer

MCF7 UMI-77 (mM) Supplementary Figure S2. Campbell et al., MCL-1 in breast cancer A MCF7 UMI-77 (mM) CRISPR BAX/BAK B CRISPR Control 36 28 BAK 28 BAX 17 130 95 72 HSP70

Campbell et al., MCL-1 in breast cancer Supplementary Figure S3. Targeting MCL-1 restricts triple negative breast cancer cell growth in vivo. A B MDA-MB-468 xenograft final weights MDA-MB-468 cells 72h siRNA treatment siControl siMCL1 Tumour weight (mg) 52 MCL-1 38 52 ACTIN 38 C siControl at endpoint siMCL1 at endpoint 55 MCL-1 36 55 ACTIN D siControl tumour at endpoint siMCL1 tumour at endpoint

Supplementary Figure S4. Requirement for Mcl1 in mammary tumourigenesis in vivo Campbell et al., MCL-1 in breast cancer A WT n=36 MMTV-PyMT;MMTV-cre;Mcl1+/+ n=8 MMTV-PyMT;MMTV-cre;Mcl1+/+; ROSA-tdRFP n=9 MMTV-PyMT;Mcl1+/+; ROSA-tdRFP n=4 MMTV-PyMT;Mcl1+/+ n=7 MMTV-PyMT;Mcl1fl/+ n=4 MMTV-PyMT;Mcl1fl/+;ROSA-tdRFP n=1 MMTV-PyMT;Mcl1fl/fl n=3 HET n=28 MMTV-PyMT;MMTV-cre;Mcl1fl/+ n=16 MMTV-PyMT;MMTV-cre;Mcl1fl/+; ROSA-tdRFP n=12 HOM n=18 MMTV-PyMT;MMTV-cre;Mcl1fl/fl n=10 MMTV-PyMT;MMTV-cre;Mcl1fl/fl; ROSA-tdRFP n=8 B Time until tumour emergence C Time for tumour progression to end point Days until tumour onset D Number of tumour burdened glands E Total tumour weight Number of glands with tumour